Phage libraries for generation of clinically useful antibodies

doi:10.1016/S0140-6736(94)92695-6

The Lancet

Volume 343, Issue 8895, 19 February 1994, Pages 455-456

https://doi.org/10.1016/S0140-6736(94)92695-6 Get rights and content

Abstract

Insertion of antibody genes into filamentous bacteriophage makes it possible to generate and screen libraries of 10⁷ or more antibodies. Each phage expresses an antibody on its surface and contains the corresponding antibody gene. Genes that encode antibodies with desired characteristics are readily selected and their antibodies expressed as soluble proteins in Escherichia coli. We used this system to produce an antibody to carcinoembryonic antigen with higher affinity and better tumour specificity than antibodies currently in use.

References (7)

Re Hawkins et al.
Selection of phage antibodies by binding affinity: mimicking affinity maturation
J Mol Biol
(1992)
Rhj. Begent
Targeted therapies: cell surface targets
J. McCafferty et al.
Phage antibodies: filamentous phage displaying antibody variable domains
Nature
(1990)

There are more references available in the full text version of this article.

Cited by (164)

Nanoparticles and trained immunity: Glimpse into the future
2021, Advanced Drug Delivery Reviews
Emerging evidences show that innate immune cells can display changes in their functional programs after infection or vaccination, which lead to immunomodulation (increased or reduced responsiveness) upon secondary activation to the same stimuli or even to a different one. Innate cells acquire features of immunological memory, nowadays using the new term of “trained immunity” or “innate immune memory”, which is different from the specific memory immune response elicited by B and T lymphocytes. The review focused on the concept of trained immunity, mostly on myeloid cells. Special attention is dedicated to the pathogen recognition along the evolution (bacteria, plants, invertebrate and vertebrate animals), and to techniques used to study epigenetic reprogramming and metabolic rewiring. Nanomaterials can be recognized by immune cells offering a very promising way to learn about trained immunity. Nanomaterials could be modified in order to immunomodulate the responses ad hoc. Many therapeutic possibilities are opened, and they should be explored.
Rapid de novo generation of antigen specific human B cells with expression of Blimp‐1 and AID by in vitro immunization
2017, Experimental Cell Research
Citation Excerpt :
It was shown that repeated injections of non-human antibodies led to a strong immune response that significantly limited or undermined their therapeutic efficacy [2,4,6]. Hence, full human mAbs have since emerged as a result of several approaches, including the phage display method and transgenic mouse system with an entire human antibody repertoire [7–12]. However, transgenic mouse system is lengthy and costly.
In vitro immunization with antigens and cytokines triggers specific human B-cell response in short periods and is therefore superior to conventional in vivo immunization for antibody development. However, this new technology is limited by low efficiency, poor reproducibility, and requirement of pre-immunized lymphocytes. In this study, we demonstrate a novel method for de novo inducing antigen-specific human B cells in vitro. Unlike previous in vitro immunization of unfractionated PBMCs, we firstly optimized the conditions for inducing monocyte-derived dendritic cells (DCs) to efficiently capture, process, and present antigens. Instead of using the conventional method to activate Th2 cells for in vitro immunization, we succeeded to differentiate naïve CD4⁺ T cells into T follicular helper (Tfh) cells using antigen-sensitized DCs and cytokine cocktail. We discovered the differentiated T cells expressed ICOS, PD-1, BCL-6, and IL-21 at high levels. After 12 days of T-B co-culture, we observed induced T cells efficiently promoted naïve B cells to differentiate into plasmablasts secreting antigen-specific antibodies, with expression of Blimp-1 and AID related to affinity maturation and class switching. Thus, we established a new co-culture system with naïve lymphocyte populations for de novo acquisition of specifically in vitro immunized B cells potentially for development of therapeutic antibodies, which also provides novel insights into understanding the complex interactions among immune cells in lymph nodes.
Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains
2012, Journal of Biological Chemistry
Citation Excerpt :
Results are shown as mean value ± S.D. ScDb-IgBD and scFv-IgBD fusion proteins were generated by fusing IgBDs from SpA, SpG, or PpL to the C terminus of a bispecific single-chain diabody directed against CEA and CD3 (scDb CEACD3) or a single-chain Fv directed against CEA (scFv CEA) (17) (Fig. 2a). From SpA we used domain B (18), domain D (9), and a modified version of domain E, which was described to exhibit increased thermal stability (19).
Many therapeutic proteins possessing a small size are rapidly cleared from circulation. Half-life extension strategies have therefore become increasingly important to improve the pharmacokinetic and pharmacodynamic properties of protein therapeutics. Here, we performed a comparative analysis of the half-life extension properties of various bacterial immunoglobulin-binding domains (IgBDs) derived from Staphylococcus protein A (SpA), Streptococcus protein G (SpG), and Finegoldia (formerly Peptostreptococcus) protein L (PpL). These domains, composed of 50–60 amino acid residues, were fused to the C terminus of a single-chain Fv and a bispecific single-chain diabody, respectively. All fusion proteins were produced in mammalian cells and retained their antigen-binding properties. The half-lives of the antibody molecules were prolonged to varying extents for the different IgBDs. The strongest effects in mice were observed for domain C3 of SpG (SpG_C3) followed by domains B and D of SpA, suggesting that SpG_C3 is particularly useful to extend the plasma half-life of small proteins.
Establishing a knowledge trail from molecular experiments to clinical trials
2011, New Biotechnology
During the development cycle of a new antibody therapy, the therapeutic agent will be tested on subsequently more biologically complex models. New experiments’ designs are based upon data gathered from prior models. New researchers who inherit the data and researchers from groups with different cultures or expertise are often called upon to interpret these data.
Experiments which are not recorded consistently or employ ambiguous terminology can make interpreting these results difficult. The researcher who had originally collected the data may not be at hand to correct any misunderstanding or offer clarification and data can be unknowingly misused. This introduces an element of risk into the therapy development process.
We have developed a reporting guideline for recording therapy experiments. This guideline consists of a checklist of data to be recorded from antibody therapy experiments performed in molecular, cellular, animal and clinical model.
Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties
2011, Journal of Biological Chemistry
Citation Excerpt :
MFE-23 is an antibody single-chain variable fragment (scFv) directed against CEA. Originally identified by phage library selection, this scFv was later humanized by resurfacing and engineered in yeast for greater stability and solubility (shMFE) as well as affinity (sm3E) (31–33). Both of these engineered molecules are well expressed in yeast and have Kd values of ∼7 nm and ∼30 pm, respectively.
Gelonin-based immunotoxins vary widely in their cytotoxic potency as a function of antigen density, target cell internalization and trafficking kinetics, and conjugate properties. We have synthesized novel gelonin immunotoxins using two different binding scaffold types (single-chain antibody variable fragments and fibronectin domains) targeting two different tumor antigens (carcinoembryonic antigen and EGF receptor). Constructs were characterized using an antigen-negative cell line (HT-1080), cell lines positive for each antigen (HT-1080(CEA) for carcinoembryonic antigen and A431 for EGF receptor), and a cell line positive for both antigens (HT-29). Immunotoxins exhibited K_d values between 8 and 15 nm and showed 20–2000-fold enhanced cytotoxicity compared with gelonin (IC₅₀ ∼ 0.25–30 nm versus 500 nm). Using quantitative fluorescence flow cytometry, we measured internalization of gelonin (via pinocytosis) and gelonin-based immunotoxins (via antigen-dependent, receptor-mediated endocytosis). Results were matched with cytotoxicity measurements made at equivalent concentration and exposures. Unexpectedly, when matched internalization and cytotoxicity data were combined, a conserved internalized cytotoxicity curve was generated that was common across experimental conditions. Considerable variations in antigen expression, trafficking kinetics, extracellular immunotoxin concentration, and exposure time were all found to collapse to a single potency curve on the basis of internalized immunotoxin. Fifty percent cytotoxicity occurred when ∼5 × 10⁶ toxin molecules were internalized regardless of the mechanism of uptake. Cytotoxicity observed at a threshold internalization was consistent with the hypothesis that endosomal escape is a common, highly inefficient, rate-limiting step following internalization by any means tested. Methods designed to enhance endosomal escape might be utilized to improve the potency of gelonin-based immunotoxins.
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors
2022, Scientific Reports

View all citing articles on Scopus

View full text

Short reportsPhage libraries for generation of clinically useful antibodies

Abstract

J Mol Biol

Targeted therapies: cell surface targets

Phage antibodies: filamentous phage displaying antibody variable domains

Nature

Short reports
Phage libraries for generation of clinically useful antibodies